about
Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease managementImaging of iron.Iron chelation in the treatment of neurodegenerative diseases.Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration.Predicting Falls in Parkinson Disease: What Is the Value of Instrumented Testing in OFF Medication State?Iron and Non-Iron-Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRIMRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7TThe neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases.Wilson disease and other neurodegenerations with metal accumulations.Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation.Moyamoya Vessel Pathology Imaged by Ultra-High-Field Magnetic Resonance Imaging at 7.0 T.Comparison of transcranial sonography-magnetic resonance fusion imaging in Wilson's and early-onset Parkinson's diseases.Narcolepsy with cataplexy and Parkinson's disease. Case Report.Pathogenesis of Wilson disease.Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.Brain iron accumulation in Wilson's disease: A longitudinal imaging case study during anticopper treatment using 7.0T MRI and transcranial sonography.Repetitive TMS of the somatosensory cortex improves writer's cramp and enhances cortical activity.Transcranial Sonography of the Insula: Digitized Image Analysis of Fusion Images with Magnetic Resonance.Brain iron accumulation in Wilson disease: a post mortem 7 Tesla MRI - histopathological study.Neuromyelitis optica does not impact periventricular venous density versus healthy controls: a 7.0 Tesla MRI clinical study.Ultrahigh-field MPRAGE Magnetic Resonance Angiography at 7.0 T in patients with cerebrovascular disease.Symptomatic treatment of neurologic symptoms in Wilson disease.Cumulative blood oxygenation-level-dependent signal changes support the 'time accumulator' hypothesis.GABA spectra and remote distractor effect in progressive supranuclear palsy: A pilot study.Psychiatric manifestations in Wilson’s disease: possibilities and difficulties for treatment.Olfaction and Colour Vision: What Can They Tell Us about Parkinson's Disease?Eye movements in idiopathic rapid eye movement sleep behaviour disorder: High antisaccade error rate reflects prefrontal cortex dysfunctionRisk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study7-Tesla Magnetic Resonance Imaging for Brain Iron Quantification in Homozygous and Heterozygous PANK2 Mutation Carriers.Neurologic impairment in Wilson disease.Validation of the REM sleep behavior disorder screening questionnaire in the Czech population.Semiquantitative Scale for Assessing Brain MRI Abnormalities in Wilson Disease: A Validation StudyMitochondrial membrane protein-associated neurodegeneration: a case report and literature reviewRelations of non-motor symptoms and dopamine transporter binding in REM sleep behavior disorderMultiparametric Quantitative Brain MRI in Neurological and Hepatic Forms of Wilson's DiseaseAlu-mediated Xq24 deletion encompassing CUL4B, LAMP2, ATP1B4, TMEM255A, and ZBTB33 genes causes Danon disease in a female patientNeurodevelopmental disorder associated with IRF2BPL gene mutation: Expanding the phenotype?Topography of emotional valence and arousal within the motor part of the subthalamic nucleus in Parkinson's diseaseEye movement abnormalities are associated with brainstem atrophy in Wilson disease
P50
Q26796643-7A519C04-93E4-41AD-B1F1-7ACC1EA1B2F5Q30691274-BC8DB3D4-461F-45DB-A35E-CAB887D00ACBQ31066051-E1B8CDC1-9DF4-47CE-8581-15B8E29ABEE9Q35694584-52B0F01D-E7B2-4D7B-BE4E-9D6FE41A28F1Q35800721-15B876A3-406C-4FA5-A227-C83DC71F5205Q37099032-6941EB73-38BD-4272-BC2A-8C45316C0945Q37123020-8918CE8E-BA90-48C5-ADB4-6C4FFFAFEC0AQ38222408-50BA376D-CF7F-4C62-9D35-593232D6B4A6Q38272513-24F5714A-A189-496F-99E5-CAB8580181DBQ38928927-A4BA80DA-C46E-44AA-B1A8-85468E13618EQ40364760-838DA419-8734-40D4-8231-692B4F9D50E1Q40371880-FA4BFA96-8E27-4926-8723-8328221A5B91Q41446831-06E91AE8-3952-486C-9019-5F964B03B328Q42508785-4241B87D-6BBF-46FE-A5D7-6ADABD0278EDQ42957249-03A4B09E-D05F-47F0-AF0A-ABA680EE7DDCQ48222881-9B9139B0-134E-432F-AA81-2B6FD4EF578BQ48230949-CADEDDF3-FC31-428F-85F9-F904B5E1D017Q48310459-D1BDB0A1-EA97-4522-B3CA-3E83E12564E2Q48515271-94FE0D49-67A3-4C01-8D4D-CE5165838204Q48560817-3C1FE04D-F4A5-4401-8DAF-0C75B98E54F8Q48746749-6F0679B3-1687-4A07-86BE-862B144ED518Q48748102-3D6CB2A7-2FFE-4974-8FA7-78173FC01CA7Q50240156-C3CC5CCB-46EF-4F8D-A940-6A1BB914AD28Q50279539-5877688F-A9D8-493E-A2B6-66B7E0E64614Q50927521-7A29C535-144F-450C-B8A7-61CA22BAAA6CQ55424779-2B2429AF-DFCD-4466-8609-EB5544182CD7Q58583072-3FD7DB68-D35C-4434-BE89-2D8841142613Q62850893-1864AACA-9DF9-4DEF-AE31-B10ABC4EDA88Q64230190-E2A7D47A-038A-4C09-B08F-C040FA2A3B6DQ64934271-682B5B23-9F26-49AB-AB86-B39B84C1BB34Q64988242-E809B15E-2F35-4158-B0C7-0185230A4E0FQ65001562-24F0A82D-85E6-4455-A022-02DAA27B65C7Q90388743-D5A15F91-D34D-4AB2-999A-7AE8EAF415BBQ90835028-C0899A35-49C8-49EC-A6D5-B6DCAE8A9735Q90999261-9C90CEC4-CF7D-414E-A568-C26B7A1ECB93Q91226888-4CF69D6F-7161-4F8E-8D3F-9C284BA21CA1Q91291026-9769A0AE-8E6C-4766-B14E-A84011807FFBQ91408366-0D0823DC-55F2-447D-A754-59CE173BC929Q92287550-4B0DD567-E926-4736-BB4F-64CC95096D27Q92387884-CE8C7FC3-EF87-4F82-9A06-4A705231EBB5
P50
description
neurolog
@cs
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Petr Dusek
@ast
Petr Dusek
@es
Petr Dusek
@nl
Petr Dušek
@cs
Petr Dušek
@en
type
label
Petr Dusek
@ast
Petr Dusek
@es
Petr Dusek
@nl
Petr Dušek
@cs
Petr Dušek
@en
prefLabel
Petr Dusek
@ast
Petr Dusek
@es
Petr Dusek
@nl
Petr Dušek
@cs
Petr Dušek
@en
P214
P1153
10042636600
P214
P31
P496
0000-0003-4877-9642
P691
jo2013795390